High-Risk Human Papillomavirus Messenger RNA Testing Using Urine, Cervicovaginal Self-Collected and Provider-Collected Cervical Samples Among Women in Mombasa, Kenya.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
pubmed:
24
2
2022
medline:
14
10
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
We compared human papillomavirus messenger RNA testing using urine, self-, and provider-collected samples for the detection of high-grade cervical cytology and assessed acceptability of urine self-collection among females who engage in sex work in Kenya. Participants found urine sampling comfortable, but high-risk human papillomavirus messenger RNA detection in urine samples was less likely to detect high-grade lesions than self- and provider-collected cervical samples.
Identifiants
pubmed: 35195617
doi: 10.1097/OLQ.0000000000001619
pii: 00007435-202211000-00010
pmc: PMC9392816
mid: NIHMS1782623
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
782-785Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190152
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA057726
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA254564
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA116339
Pays : United States
Informations de copyright
Copyright © 2022 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: J.S.S. has received unrestricted educational grants, consultancy, and research grants from Merck Corporation and GlaxoSmithKline over the past 5 years. R.S.M. has received honoraria for consulting from Lupin Pharmaceuticals and research funding, paid to the University of Washington, from Hologic Corporation. All other authors have no conflicts to declare.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12–19.
Olson B, Gribble B, Dias J, et al. Cervical cancer screening programs and guidelines in low- and middle-income countries. Int J Gynecol Obstet 2016; 134:239–246.
Rohner E, McGuire FH, Liu Y, et al. Racial and ethnic differences in acceptability of urine and cervico-vaginal sample self-collection for HPV-based cervical cancer screening. J Women's Health (Larchmt) 2020; 29:971–979.
Pathak N, Dodds J, Zamora J, et al. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: Systematic review and meta-analysis. BMJ 2014; 349:g5264.
Senkomago V, Des Marais AC, Rahangdale L, et al. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. J Clin Virol 2015; 74:26–31.
Asciutto KC, Ernstson A, Forslund O, et al. Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. J Clin Virol 2018; 101:69–73.
Islam JY, Mutua MM, Kabare E, et al. High-risk human papillomavirus messenger RNA testing in wet and dry self-collected specimens for high-grade cervical lesion detection in Mombasa, Kenya. Sex Transm Dis 2020; 47:464–472.
Eperon I, Vassilakos P, Navarria I, et al. Randomized comparison of vaginal self-sampling by standard vs. dry swabs for human papillomavirus testing. BMC Cancer 2013; 13:353.
Manguro GO, Masese LN, Mandaliya K, et al. Preference of specimen collection methods for human papillomavirus detection for cervical cancer screening: A cross-sectional study of high-risk women in Mombasa, Kenya. Reprod Health 2018; 15:206.
Rohner E, Rahangdale L, Sanusi B, et al. Test accuracy of human papillomavirus in urine for detection of cervical intraepithelial neoplasia. J Clin Microbiol 2020; 58:e01443–e01419.
Ting J, Mugo N, Kwatampora J, et al. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya. Sex Transm Dis 2013; 40:584–589.
Iftner T, Neis KJ, Castanon A, et al. Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol 2019; 57:e01177–e01118.
Monsonego J, Hudgens MG, Zerat L, et al. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study) ☆. Gynecol Oncol 2012; 125:175–180.